Feryal Alhamadani, PharmD

Articles by Feryal Alhamadani, PharmD

Elranatamab-bcmm Approved for Adult Patients With Relapsed or Refractory Multiple Myeloma

ByFeryal Alhamadani, PharmD,Kevin W. Chamberlin, PharmD, FASCP

February 21st 2024

The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.

Feryal Alhamadani, PharmD

Articles by Feryal Alhamadani, PharmD

Elranatamab-bcmm Approved for Adult Patients With Relapsed or Refractory Multiple Myeloma

Latest Updated Articles

Trending on Drug Topics

MDPNP Implementation Will Be Complex Despite Systems Properly in Place | NCPA 2025

Q&A: Why Community Pharmacies are Displeased with the MDPNP | NCPA 2025